Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

THERAPY OF ENDOCRINE DISEASE: Amylin and calcitonin - physiology and pharmacology

Research output: Contribution to journalReviewResearchpeer-review

DOI

  1. Dynamic Changes in LH/FSH Ratios in Infants with Normal Sex Development

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Randomized Controlled Trial of Tesomet for Weight Loss in Hypothalamic Obesity

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Increased liver fat associates with severe metabolic perturbations in low birth weight men

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The Glucagon Receptor Antagonist LY2409021 has No Effect on Postprandial Glucose in Type 2 Diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. MECHANISMS IN ENDOCRINOLOGY: The physiology of neuronostatin

    Research output: Contribution to journalReviewResearchpeer-review

  1. Beta-hydroxybutyrate suppresses hepatic production of the ghrelin receptor antagonist, LEAP2

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Effect of Meal Texture on Postprandial Glucose Excursions and Gut Hormones After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Type 2 diabetes is a common manifestation of metabolic dysfunction due to obesity and constitutes a major burden for modern health care systems, in concert with the alarming rise in obesity worldwide. In recent years, several successful pharmacotherapies improving glucose metabolism have emerged and some of these also promote weight loss, thus, ameliorating insulin resistance. However, the progressive nature of type 2 diabetes is not halted by these new anti-diabetic pharmacotherapies. Therefore, novel therapies promoting weight loss further and delaying diabetes progression are needed. Amylin, a beta cell hormone, has satiating properties and also delays gastric emptying and inhibits postprandial glucagon secretion with the net result of reducing postprandial glucose excursions. Amylin acts through the six amylin receptors, which share the core component with the calcitonin receptor. Calcitonin, derived from thyroid C cells, is best known for its role in humane calcium metabolism, where it inhibits osteoclasts and reduces circulating calcium. However, calcitonin, particularly of salmon origin, has also been shown to affect insulin sensitivity, reduce the gastric emptying rate and promote satiation. Preclinical trials with agents targeting the calcitonin receptor and the amylin receptors, show improvements in several parameters of glucose metabolism including insulin sensitivity and some of these agents are currently undergoing clinical trials. Here, we review the physiological and pharmacological effects of amylin and calcitonin and discuss the future potential of amylin and calcitonin-based treatments for patients with type 2 diabetes and obesity.

Original languageEnglish
Article number1261
JournalEuropean Journal of Endocrinology
Volume186
Issue number6
Pages (from-to)R93-R111
Number of pages19
ISSN0804-4643
DOIs
Publication statusPublished - 21 Apr 2022

ID: 76296930